STUDIE 2000 - 2003 ACUTE 2: Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin vs unfractionated heparin in patiens with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE 2 study. Am Heart J 2002; 22: 470-477
ADMIRAL: Montalescot G., Barragan P., Wittenberg O. et al. Platelet glycopro-tein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903.
ADVANCE: Serruys, PW, Foley, DP, Suttorp, MJ, et al A randomized comparison of value of additional stenting after optima balloon angioplasty for long coronary lesions. J Am Coll Cardiol 2002; 39: 393-399.
AFFIRM: AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. New Engl J Med 2002; 347: 1825- 1833.
AFIRME: Catella-Lawson F., Kapoor S., Moretti D. et al. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. Am J Cardiol 2001; 88:236-242
AFIST: Giri S., White C.M., Dunn A.B. et al. Oral amiodarone for prevention of atrial fibrilation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001; 257: 830-836
ALIVE: Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with li-docaine for shock- resistant ventricular fibrillation. N Engl J Med 2002; 346: 884- 890
ALLHAT:The ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997
ALLHAT-LLT: The ALLHAT-LLT Officers. Major outcomes in moderately hypercholesterolemic, hypertensive patiens randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart At-tack Trial (ALLHAT-LLT). : JAMA 2002; 288: 2998 - 3007
AMI-SK : Simoons ML, Krzeminska-Pakula M, Alfonso A et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Eur Heart J 2002; 25: 1282-1290
AMORIS: Walidius G., Jungner I., Holme I. et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033
ANBP2: Wing L.M.H., Reid C.M., Ryan P., et al. A comparison for outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 2003; 348: 583–92.
APRICOT-2: Brouwer MA, van den Bergh PJPC, Aengevaeren WRM, et al.Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction.Circulation 2002; 106: 659-665
ARBROATH: MacFadyen R.J.., MacLeod C.M., Shiels P. et al. Isolated diastolic heart failure as a cause of breathlessness in the community. Eur. J. Heart Failure 2001; 3: 243-248
ARTIST: von Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not redukce recurrent in-stent restenosis. Circulation 2002; 105: 583-588
ARTS: Van den Brand M.J., Rensing B.J., Morel M.A. et al. The effect of com-pleteness of revascularization on event-free survival at 1 year in ARTS trial. J Am Coll Cardiol 2002; 39: 559 - 564.
ASAP: Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
ASCOT-LLA: Sever PS, Dahl B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in th Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm: a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.
ASPECT : Park, SJ., Shim, WH, Ho, DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis.N Engl J Med 2003; 348: 1537-1545.
ASPECT-2: van Es RF, Jonker, JJ., Verheugt, FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2): a randomised controlled trial. Lancet 2002; 360: 109-113.
ASSENT Plus: Wallentin L, Bergstrand L, Dellborg M, et al.Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction – the ASSENT Plus study. Eur Heart J 2003; 24: 897-908
ASSENT-2: Van de Werf F., Barron H.V., Armstrong P.W. et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. A comparison of TNK-tPA and rt-PA. Eur Heart J 2001; 22: 2253-2261.
ASSENT-3: Werf de Werf F., Armstrong P.W, Granger C., et al.Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 338: 605-613
ATLAST: Batchelor W., B., Mahaffey K.W., Berger P.B. et al. A randomized, Placebo- Controlled Trial of Enoxaparin After High-Risk Coronary Stenting. J Am Coll Cardiol 2001; 38: 1608-13.
AZACS: Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patiens with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-813
BCAPS: Hedblad B., Wikstrand J., Janzon L.,et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS) Circulation 2001; 103: 1721-1726
BENESTENT-I: Kiemeneij F., Serruys P.W., Macaya C.,et al. Continued Benefit of Coronary Stenting Versus Balloon Angioplasty: Five-Year Clinical Follow-Up of Benestent-I Trial. J Am Coll Cardiol 2001; 37: 1 590-1 603
BEST: BEST Investigators. Beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1 659- 1 667
BLOS: Connolly SJ, Cybulsky I, Lamy A, et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the BLOS study. Am Heart J 2003; 145: 226 – 232
BREATHE-1: Rubin, LJ, Badesch, DB, Barst, RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903
CAPRICORN: The CAPRICORN Investigators.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction.Lancet 2001;358:1385-90.
CAPTIM: Bonnefoy E, Lapostolle F, Leizorovicz A, et al.Primary angioplasty vs prehospital fibrinolysis in acute myocardial infarction; a randomised study. Lancet 2002; 360: 825-829
CARS: O´Connor M.Ch., Gattis W.A., Hellkamp A.S., et al. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the Warfarin (Coumadin) Aspirin Reinfarction Study (CARS). Am J Cardiol 2001; 88: 541-546
CASTLE: Kloner R.A. Weinberger M., Pool J.L.,et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol 2001; 87: 727-731
Clopidogrel vs ticlopidin: Hunziker P, Marsch S, Perruchoud A, Buettner HJ. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspi-rin after the placement of coronary artery stents. J Am Coll Cardiol 2003; 41: 969- 73
COAST: Haude M, Konorza TFM, Kalnins U, et al. Heparin-coated stent pla-cement for the treatment of stenoses in small coronary arteries of symptomatic patients.Circulation 2003; 107: 1265- 1270
COMET: Poole-Wilson PA,, Swedberg K, Cleland JGF,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial: randomised controlled trial. Lancet 2003; 362: 7-13
COMPLIOR: Asmar R., Topouchian J., Pannier B., et al. Pulse wave velocity as endpoint in large-scale intervention trial.The Complior study. J Hypertens 2001; 19: 813-818
COOPERATE: Nakao, N, Yoshimura, A, Morita, H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124
COPERNICUS: Packer M., Coats A.J.S., Fowler M.B., et al. The Carvedilol Prospektive Randomized Cumulative Survival Study. N Engl J Med 2001; 344: 1651-1658.
CREDO: Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002; 288: 2411-2420
CURE: Yusuf S., Fox K.A.A., Tognoni G. et al. Effects of Clopidogrel in addi-tion to Aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
Cutting Balloon Global Randomized Trial: Mauri L, Bonan R, Weiner BH et al.Cuttining balloon angioplasty for the prevention of restenosis: results of the cutting balloon global randomized trial. Am J Cardiol 2002; 90: 1079 – 1083.
DANAMI – 2: Anderson H.R., Nielsen T.T., Rasmussen K., et al. on behalf of The Danish Multicenter Randomized Study on Fibrinolytic Therapy versus Acute Myocardial Infarction. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733–42.
DANSTENT: Jorgensen, E, Kelbaek, H, Helqvist, S, et al. Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DANSTENT) – a randomized trial comparing a first-generation stent with a se-cond-generation stent.Am Heart J 2003; 145: e 5.
DAVID: DAVID Investigators.Dual-chamber pacing or ventricular backup pa-cing in patients with an implantable defibrillator. JAMA 2002; 288: 3115 – 3123.
DIRECT: Brito FS, Caixeta AM, Perin MA, et al.Comparison of direct stenting vs stenting with predilation for the treatment of selected coronary narrowings. Am J Cardiol 2002; 89: 115-120
ELATE: Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term pre-vention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631 –639
ELSA: Zanchetti, A, Bond, MG, Hennig, M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotic atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomised, double-blind, long-term trial. Circulation 2002; 106: 2422-2427
ENCORE I: Investigators ENCORE study. Effect of nifedipine and cerivastatin on coronary endothelial function in patiens with coronary artery disease. Circu-lation 2003; 107: 422-428
ENTIRE-TIMI-23: Altman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST elevation myocardial infarction. Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105: 1642-1649
EPHESUS: Lassen MR, Bauer KA, Eriksson BIA, et al.Postoperative fondaparinux vs preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. : Lancet 2002; 359: 1715 - 1720
EPHESUS: Pitt B., Remme W., Zannad F.et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003; 348: 1309-1321
ERAFT: Meinertz T, Lip GY, Lombardi F, et al.Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation. Am J Cardiol 2002; 90: 1300 – 1306
ESCAMI: Zeymer U., Suryapranata J.P.M., Opolski G., et al.The Na+/H+ Exchange Inhibitor Eniporide as an adjunct to Early Reperfusion Therapy for Acute Myocardial Infarction: Results of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) Trial. J Am Coll Cardiol 2001; 38 (6): 1644 – 1649
ESPRIT: Schneider, TL, Hopp, HW, Vlaho, D, et al. Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the ESPRIT stu-dy.Am Heart J 2003; 145: e5.
ESSENCE:Goodman SG, Cohen M, Bigonzi F, et al. Randomized Trial of Low Molecular Weight Heparin (Enoxaparin) versus Unfractionated Heparin for Un-stable Coronary Artery Disease.J Am Coll Cardiol 2001; 36: 693-8.
ESTEEM: Wallentin L, Wilcox RG, Weaver WD, et al.Oral ximelagatran for secondary prohylaxis after myocardial infarction: the ESTEEM randomized con-trolled trial. Lancet 2003; 362: 789-97.
EUROPA: Fox K.M., Bertrand M., Ferrari R.,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controled, multicentre trial. Lancet 2003; 362: 782-88.
FLORIDA: Liem AH, van Boven AJ, Veeger NJ, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002; 23: 1931-1937 GREACE: Athyros VG, Papageorgiou AA, Mercouris BR, et al.Treatment with atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention. Curr Med Res Opin 2002; 18: 220 – 228 GUSTO IV James S.K., Lindahl B., Siegbahn A., et al. N-Terminal Pro-Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease Circulation.2003; 108: 275 – 281. GUSTO IV: Ottervanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina. Circulation 2003; 107: 437-442
GUSTO IV-ACS: Simoons M.L., Armstrong P., Califf R., et al. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial Lancet 2001; 357: 1915-1924.
GUSTO V: Lincoff A M, Califf RM, Van de Werf F, et al.Mortality at 1 year with combination platelet glycoprotein IIb/III inhibition and reduced-dose fibrinolytic therapy vs convetional fibrinolytic therapy for acute myocardial infarction. GUSTO V randomized trial. JAMA 2002; 288: 2130-2135
GUSTO V: Topol J.E. za řešitele studie GUSTO V. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fib-rinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V ran-domised trial. Lancet 2001; 357: 1 905-1 914
HERO-2: Nakov R. on behalf of HERO-2 Investigators.. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction. Lancet 2001; 358: 1855-1863
HERS II: Herrington, DM, Vittinghoff, E, Lin, F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105: 2962-2967
CHALLENGE: Karalis DG, Ross AM, Vacari RM, et al. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cadiol 2002; 89: 667 – 671
CHAMP: Fiore LD, Ezekowitz MD, Brlohy MT, et al. Department of veterans affairs kooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP Study. Circulation 2002; 105: 557-563
CHARM: Pfeffer M.A., Swedberger K., Granger C.B., et al.Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM – Overall programme. Lancet 2003; 362: 759-766,
IDNT: Lewis E.J., Hunsicker L.G., Clarke W.R.,et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
INSIGHT: Simon A., Gariépy J., Moyse D.,et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2 949-2 954
INTERACT: Goodman SG, Fitchet D, Armstrong PW, et al.Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein Iib/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238 – 244.
Intracoronary vs Intravenous ABCIXIMAB in ACS: Wohrle J, Grebe O, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patiens with acute myocardial infarction or unstable angina undergoing coronary angiography. Cir-culation 2003; 107: 1840-1843.
INTRO AMI: Brener SJ, Zeyer U, Adgey A A J, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. The Integrilin and Low-Dose Thrombolysis in Acute Myocardial Infarction (INTRO AMI) trial. J Am Coll Cardiol 2002; 39: 377-386
INVEST: Pepine CJ, Handber EM, Cooper-Dehoff RM et al. A Calcium Antagonist vs Calcium Antagonist Hypertension Treatment Strategy ifor Patiens with- Coronary Artury Disease.The International Verapamil-Trandolapril Study (INVEST). JAMA 2003;290: 2805-2820
IONA: IONA Investogators. Effect of nicorandil on coronary events in patiens with stable angina: the Impact of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-1275
IRMA: Parving H.H., Lehnert H., Mortensen J. B., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
ISAR-STEREO: Katrati A., Mehilli J., Dirschinger J., et al. Intracoronary Sten-ting and Angiographic Results - Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial. Circulation. 2001; 103: 2 816-021
ISAR–STEREO-2: Pache, J, Kastrati, A, Mehilli, J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome trial. J Am Coll Cardiol 2003; 41: 1283-1288.
LIDO: Follath, F, Cleland, JGC, Just, H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202
LIFE: Dahlof, B, Devereux, RB, Kjeldsen, S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
LIPS: Serruys PWJC, de Feyter P, Macaya C, et al.Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002; 287: 3215- 3222
MADIT II: Moss AJ, Zareba W, Hall WJ, et al.Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877 – 883.
MAGIC: MAGIC Investigators Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coro-naries (MAGIC) trial: a randomised controlled trial. Lancet 2002; 360: 1189-1196
MARVAL: MARVAL Investigators. Microalbuminuria Reduction with Valsar-tan in patients with type 2 diabetes mellitus: a blood pressure independent effect. Circulation 2002; 106: 672-678.
MIRACL: Schwartz G.G., Olsson A.G., Ezekowitz M.D et al. . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The Miracl Study: A randomized controlled trial. JAMA 2001; 285: 1 711-1 718
MIRACLE ICD: Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. The Miracle ICD trial. JAMA 2003; 289: 2685 - 94
MIRACLE: Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. Multicenter InSync Randomized Clinical Evalution. N Engl J Med 2002; 346: 1845 - 1853.
MOST: Lamas G.A., Lee K.L., Sweeney M.O. et al. Ventricular pacing or dual-chamber for sinus node dysfunction. N Engl J Med 2002; 346: 1854- 1862.
MOXCON: Cohn JN, Pfeffer MA, Rouleau J et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Europ J Heart Failure 2003; 5: 659-667.
MRC/BHF Heart Protection Study: Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361:2005-16.
MUSTT: Wyse DG., Talajic M.,Hafley GE. et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis. J Am Coll Cardiol 2001; 38: 344-351
NICOLE: Dens J.A., Desmet W.J., Coussement P., et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 2001; 87: 28-33
OPTIMAAL: Dickstein K, Kjekshus J and OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patiens after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002; 360: 752-760
OPTIME-CHF: Caffe, MS, Califf, RM, Adams, KF, et al. Short-term intrave-nous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. JAMA 2002; 287: 1541-1547
OVERTURE: Packer M.,Calliff R.M.,Konstam M.A. et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation 2002; 106: 920-926
PACIFIC: PACIFIC Investigators. Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals wi-th coronary heart disease. Eur Heart J 2002; 23: 1509-1515
PARAGON B: PARAGON B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002; 105: 316-321
PCI-CURE: (podstudie studie CURE): Mehta S.R., Yusuf S., Peters R.J.G.,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary interventions: the PCI-CURE study. Lancet 2001; 358: 527-533
PPP: Byington R.P., Davis B.R., Plehn J.F.,et al. Reduction of Stroke Events With Pravastatin. Circulation 2001; 103: 387-392
PRAGUE-2: Widimský P, Budesinský T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicenter trial – PRAGUE-2. Eur Heart J 2003; 24: 94-104
PRECEDENT: Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhyhmias in the treat-ment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J 2002; 144: 1102 – 1108
PRESERVE: Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily Angiotensin-converting enzyme inhibition and calcium channel blockad-based antihypertensive treatment regimens on lef ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) Trial. Circulation 2001; 104: 1248-1254
PRESTO: Holmes DR, Savage M, LaBlanche JM et al. Results of Prevention of Restenosis with Tranilast and Its Outcomes ( PRESTO) Trial. Circulation 2002; 106: 1243-1250
PREVENT: Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembo-lism. N Engl J Med 2003; 348: 1452 – 1434
Primary Prevention Project. Primary Prevention Project Investigators. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95
PRIME: Prime Investigators. Multicenter, dose-ranging study of efegatran sulfate vs heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion In Myocardial Infarction Evolution (PRIME) trial. Am Heart J 2002; 143: 95 – 105
PRINCE: Alber M.A., Danielson E., Rifai N.et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.JAMA 2001; 286: 64-70
PROGRESS: Řešitelé studie PROGRESS.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1 033-1 041
PROSPER: . Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623 - 1630.
QUIET: Pitt B., O´Neil B., Reldman R.,et al. The Quinapril Ischemic Event Trial (QUIET): Evaluation of Chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1 058 – 1 063
QUO VADIS: Oosterga M., Voors A.A., Yigal M.P., et al. Effect of Quinalapril on Clinical Outcome After Coronary Artery Bypass Grafting (The QUO VADIS Study). Am J Cardiol 2001; 87: 542-546
RAVEL: Morice, MC, Serruys, PW, Sousa, JE, et al A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
RENAAL: Brenner B.M., Cooper M.E., Zeeuw D., et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropa-thy. N Engl J Med 2001; 345: 861-869
REPLACE: Dunselman P.H.J.M on behalf of REPLACE .Effects of the repla-cements of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. Int J Cardiol 2001; 77: 131-138
RITA 3: Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002; 360: 743 – 751.
RITZ-4: O´Connor, CM, Gattis, WA., Adams, KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes. Results of RITZ-4. J Am Coll Cardiol 2003; 41: 1452-1457
RUSSLAN: Moseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422 – 1432
SCOPE: Lithell H, Hansson L, Skoog I, et al.The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875 – 886
SECURE: (podstudie studie HOPE): Lonn E.M., Yusuf S., Dzavik V.,et al. Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation 2001; 103: 919-925
SIRIUS: Moses JW, Leon MB, Pompa JJ et al. Sirolimus- eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
SMILE-2: Borghi C, Ambrosioni E on behalf of SMILE-2. Double-blind comparsion between zofenopril and lisinopril in patiens with acute myocardial infarction: results od the SMILE-2 study. Am Heart J 2003; 145: 80-87
SOS:SOS Investigators Coronary artery bypass surgery vs percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial.Lancet 2002; 360: 965-970.
SPORTIF II: Peterson P, Grind M, Adler J, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II. A dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003; 41: 1445 – 1451.
SPORTIF III: Albers GW, Diener HC, Grind M et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in pati-ents with non – valvular atrial fibrillation. Lancet 2003; 362: 1691-98.
STAF: Carlsson J, Miketic S, Windeler J, et al.Randomized trial of rate-control vs rhytm-control in persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1690 – 1696
STAMI: Scrutinio D., Cimminiello C., Marubini E. et al. Ticlodipine versus Aspirin after Myocardial Infarction Trial. J Am Coll Cardiol 2001; 37: 1 259-1 265
STELLAR: Jones PH , Davidson MH, Stein EA et al. Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses Am J Cardiol 2003; 92: 152 - 160
SYMPHONY: Investigators of study SYMPHONY. Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes (dodatečná analýza). Circulation 2001; 103: 1727 – 1733 (původní reference Lancet 2000; 355: 337-45)
TACTICS - TIMI 18: Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Eng J Med 2001; 344: 1 879 – 1 887
TARGET: Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1 888-1 894
TENISS : Unverdorben, M, Sippel, B, Degenhardt, R, et al. Comparison of a si-licon carbide-coated stent vs a noncoated stent in human beings: the Tenax vs NIR stent study´s long-therm outcome. Am Heart J 2003; 145: e 17
THRIVE III: Schulman S, Wåhlander K, Lundström T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713 – 1721.
TORIC: Cosín J, Díez J. et al. Torasemide in chronic heart failure: results of the TORIC study. Europ J Heart Failure 2003; 4: 507 – 513
TPT (Angina): Knottenbelt C, Brennan PJ, Meade TW, et al. Antithrombotic treatment and the incidence of angina pectoris. Arch Intern Med 2002; 162: 881-886
TRIMPOL II. Szwed H., Sadowski Z., Elikowski W.,et al. Combination treat-ment in stable effort angina using trimetazidine and metoprolol. Eur Heart J 2001; 22: 2 267 – 2 274
VA-HIT: Rubins H.B., Davenport J., Babikan V.,et al. The VA HDL Interventi-on Trial (post hoc analýza) Circulation 2001; 103: 2 828-2 833
VAL HeFT: Cohn J.N., Tognoni G. on behalf of study Val HeFT.:A randomi-zed trial of the angiotensin-receptor blocker valsartan in chronic heart failure.N Engl J Med 2001; 345: 1 667-1 675
Val- PREST: Peters S., Goetting B., Truemmel M.,et al. Valsartan for Prevention of Restenosis After Stenting of Type B2/C Lesions. J Inv Cardiology 2001;13: 93-97
VALIANT: Pfeffer MA, McMurray JJ, Velazquez EJ,et al.Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dys-function, or both. N Engl J Med 2003; 349: 1893 – 906
VINO: Špaček R, Widimský P, Straka Z, et al. Value of first day coronary angiography/angioplasty in evolving non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO study. Eur Heart J 2002; 23: 230-238
VMAC: The VMAC Investigators. Intravenous neseritide vs nitroglycerin for treatment of decompesated congestive heart failure. JAMA 2002; 1531-1540
Warfain, ASA or both: Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspi-rin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974
WARSS: Mohr J.P, Thompson J.L.P., Laza R.M., et al. A comparison of warfarin and aspirin for the prevention of reccurent ischemic stroke. N Engl J Med 2001; 1345:1 444 – 1 451.
WHI: Manson J.E., Hsia J., Johnson K.C. et al. ,Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.